Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib

Leukemia Research

Volumn 34, Issue 8, 2010, Pages

  Ikezoe, Takayuki ^a   Togitani, Kazuto ^a   Tasaka, Taizo ^b   Nishioka, Chie ^a   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE;

ABSENCE OF SIDE EFFECTS; ADULT; BONE MARROW EXAMINATION; CASE REPORT; DRUG DOSE INCREASE; EOSINOPHILIA; ERYTHRODERMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; LEUKOCYTE COUNT; MALE; MISSENSE MUTATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77953628107     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.024     Document Type: Letter

References (7)

1. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
2. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007, 67:3759-3766.
3. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Prog 2009, 461-476.
4. Lierman E., Michaux L., Beullens E., Pierre P., Marynen P., Cools J., et al. FIP1L1-PDGFRalpha D842V, a novel pan resistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
5. Nishioka C., Ikezoe T., Yang J., Miwa A., Tasaka T., Kuwayama Y., et al. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008, 111:5086-5092.
6. Lierman E., Folens C., Stover E.H., Mentens N., Van Miegroet H., Scheers W., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
7. von Bubnoff N., Gorantla S.P., Thöne S., Peschel C., Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971.